Advancements in the Management of R/R AML: ASH 2024 - Episode 3

Navigating Challenges in Second- and Third-Line AML Therapy

January 10, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss how treatment goals in the second- and third-line settings for relapsed/refractory acute monocytic leukemia (R/R AML) now focus more on disease control, quality of life, and prolonging survival, and explore the most significant unmet needs in R/R AML, particularly in addressing drug resistance and optimizing therapeutic strategies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

EP. 2: Treatment Goals and Unmet Needs in R/R AML

Now Viewing

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP. 9: Genetic Testing and Molecular Profiling in AML

EP. 10: Emerging Combination Strategies and Preclinical Findings

EP. 11: Future Perspectives on Menin Inhibitors in Acute Leukemias

EP. 12: Closing Perspectives on R/R AML Treatment Advances

Video content above is prompted by the following:

Outside of cure, what are the treatment goals in the second-line and third-line setting?
How have these goals changed based on the recent changes within the AML landscape?
What do you see as the most significant unmet need in R/R AML?